Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 312
Filter
1.
Études Anglaises ; 75(1):46-66,120-121, 2022.
Article in French | ProQuest Central | ID: covidwho-1823838

ABSTRACT

Au sein de l'histoire militante des travaux d'aiguille, le patchwork américain, souvent engage sur le terrain politique et social, s'est a plusieurs reprises associé a des initiatives de santé publique. Dans la continuité du NAMES Memorial AIDS Quilt, projet majeur datant de 1987, la récente crise sanitaire du COVID-19 a été l'occasion d'un renouvellement de la pratique, exprimant une mobilisation solidaire (notamment par la confection de masques), un partage de l'expérience sensible a la croisée de l'expression personnelle et de l'articulation symbolique et au-dela, une dynamique de résistance politique en période de confinement. Le parcours critique proposé ici, fondé sur l'observation de projets individuels ou collectifs, vise a explorer comment le patchwork, croisant restriction et invention, se construit comme un nouveau vecteur d'opinion dans les combats sociétaux contemporains, au sein de la culture matérielle (dont il releve) et immatérielle (qui le prolonge).Alternate :Within the militant history of needlework, the American quilt, often politically and socially engaged, has repeatedly been associated with public health initiatives. In the continuity of the NAMES Memorial AIDS Quilt, a major project dating from 1987, the recent health crisis of COVID-19 was an opportunity for renewal of the practice. The collective effort of making face masks, as well as other creative sewing initiatives, demonstrated a will to endure and a desire to share the experience at the crossroads of personal expression and symbolic articulation, and beyond this, a dynamic of resistance during a period of lockdown. The critical journey proposed here, based on the observation of individual experiences or collective projects, aims to explore how patchwork, combining restriction and invention, is constructed as a new vector of opinion in contemporary societal struggles, within material culture (from which it arises) and immaterial culture (which prolongs it).

2.
Vaccines ; 10(4), 2022.
Article in English | EMBASE | ID: covidwho-1822466

ABSTRACT

The COVID-19 pandemic continues to be a worldwide health issue. Among hemodialysis (HD) patients, two-dose immunization schemes with mRNA vaccines have contributed to preventing severe COVID-19 cases;however, some have not produced a sufficient humoral response, and most have developed a rapid decline in antibody levels over the months following vaccination. This observational, prospective, multi-center study evaluated the humoral response in terms of presence and levels of IgG antibodies to the receptor-binding domain of the S1 spike antigen of SARS-CoV-2 (anti-S1-RBD IgG) to the third dose of SARS-CoV-2 mRNA vaccines, either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer), in 153 patients from three dialysis units affiliated to Hospital Clínic of Barcelona (Spain). Most hemodialysis patients responded intensely to this third vaccine dose, achieving the seroconversion in three out of four non-or weak responders to two doses. Moreover, 96.1% maintained the upper limit or generated higher titers than after the second. BNT162b2 vaccine, active cancer, and immunosuppressive treatment were related to a worse humoral response. Every hemodialysis patient should be administered a third vaccine dose six months after receiving the second one. Despite the lack of data, immunosuppressed patients and those with active cancer may benefit from more frequent vaccine boosters.

3.
Cells ; 11(9), 2022.
Article in English | EMBASE | ID: covidwho-1822414

ABSTRACT

The p53-dependent ubiquitin ligase Pirh2 regulates a number of proteins involved in different cancer-associated processes. Targeting the p53 family proteins, Chk2, p27Kip1, Twist1 and others, Pirh2 participates in such cellular processes as proliferation, cell cycle regulation, apoptosis and cellular migration. Thus, it is not surprising that Pirh2 takes part in the initiation and progression of different diseases and pathologies including but not limited to cancer. In this review, we aimed to summarize the available data on Pirh2 regulation, its protein targets and its role in various diseases and pathological processes, thus making the Pirh2 protein a promising therapeutic target.

4.
Frontiers in Microbiology ; 13, 2022.
Article in English | EMBASE | ID: covidwho-1822383

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of the COVID-19 pandemic, is initiated by its binding to the ACE2 receptor and other co-receptors on mucosal epithelial cells. Variable outcomes of the infection and disease severity can be influenced by pre-existing risk factors. Human immunodeficiency virus (HIV), the cause of AIDS, targets the gut mucosal immune system and impairs epithelial barriers and mucosal immunity. We sought to determine the impact and mechanisms of pre-existing HIV infection increasing mucosal vulnerability to SARS-CoV-2 infection and disease. We investigated changes in the expression of ACE2 and other SARS-CoV-2 receptors and related pathways in virally inflamed gut by using the SIV infected rhesus macaque model of HIV/AIDS. Immunohistochemical analysis showed sustained/enhanced ACE2 expression in the gut epithelium of SIV infected animals compared to uninfected controls. Gut mucosal transcriptomic analysis demonstrated enhanced expression of host factors that support SARS-CoV-2 entry, replication, and infection. Metabolomic analysis of gut luminal contents revealed the impact of SIV infection as demonstrated by impaired mitochondrial function and decreased immune response, which render the host more vulnerable to other pathogens. In summary, SIV infection resulted in sustained or increased ACE2 expression in an inflamed and immune-impaired gut mucosal microenvironment. Collectively, these mucosal changes increase the susceptibility to SARS-CoV-2 infection and disease severity and result in ineffective viral clearance. Our study highlights the use of the SIV model of AIDS to fill the knowledge gap of the enteric mechanisms of co-infections as risk factors for poor disease outcomes, generation of new viral variants and immune escape in COVID-19.

5.
Current Opinion in Organ Transplantation ; 27(1):36-44, 2022.
Article in English | EMBASE | ID: covidwho-1821995

ABSTRACT

Purpose of review Heart failure incidence continues to rise despite a relatively static number of available donor hearts. Selecting an appropriate heart transplant candidate requires evaluation of numerous factors to balance patient benefit while maximizing the utility of scarce donor hearts. Recent research has provided new insights into refining recipient risk assessment, providing additional tools to further define and balance risk when considering heart transplantation. Recent findings Recent publications have developed models to assist in risk stratifying potential heart transplant recipients based on cardiac and noncardiac factors. These studies provide additional tools to assist clinicians in balancing individual risk and benefit of heart transplantation in the context of a limited donor organ supply. Summary The primary goal of heart transplantation is to improve survival and maximize quality of life. To meet this goal, a careful assessment of patient-specific risks is essential. The optimal approach to patient selection relies on integrating recent prognostication models with a multifactorial assessment of established clinical characteristics, comorbidities and psychosocial factors.

6.
European Journal of Molecular and Clinical Medicine ; 9(3):2605-2612, 2022.
Article in English | EMBASE | ID: covidwho-1820595

ABSTRACT

Introduction: Mortality rates for COVID-19-related mucormycosis vary greatly in reported studies. A systematic evaluation of 101 cases revealed a fatality rate of 30.7 percent. However, research on the determinants of death in COVID-19 associated mucormycosis is insufficient. The purpose of this study was to find out what factors contributed to in-hospital mortality in patients with COVID-19-related mucormycosis. Objectives: To study the the Clinical profile, Haematological,Biochemical and Radiological changes associated with mortality in patients with covid-19 associated mucormycosis. Methodology: In this single-center, observational study, 130 patients diagnosed with COVID-19 associated mucormycosis were recruited from a tertiary level intensive care unit from Bowring and Lady Curzon hospital, Bangalore, India. Results: Proportion of HTN, IHD, CKD and HIV was significantly more in non survivors compared to survivors. ICU admission and Oxygen requirement was scientifically higher in Non Survivors and had significant association with the outcome.. There was no significant difference in the levels of Hb, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Platelets as p>0.05. Total count (17191±7764), ESR (57.6±12.4), CRP levels (199.0±69.5), and S.Ferritin (624.6±268.0) were significantly higher among the Non survivors. S.LDH (355.7±108.9), S.Free Iron (51.7±13.3), HBA1C (11.4±2.4), and S.Urea (36.9±35.3) were also found to be significantly higher among the non survivors. Conclusion: The current study highlights that a multidisciplinary approach in COVID-19 associated mucormycosis patients that includes timely and effective surgical debridement coupled with appropriate antifungal therapy and diligent sugar monitoring with intrahospital glycemic control may help to lower mortality.

7.
Transplantology ; 3(1):83, 2022.
Article in English | ProQuest Central | ID: covidwho-1818208

ABSTRACT

Immunocompromised patients with respiratory viral infections are at increased risk of fungal superinfections, including Pneumocystosis. Within the scope of the COVID-19 pandemic, Pneumocystis jirovecii co-infections are being increasingly reported. Differential diagnosis often creates a dilemma, due to multiple overlapping clinical and radiographic features. Awareness of fungal co-infections in the context of the COVID-19 pandemic is crucial to initiate prophylactic measures, especially in high-risk individuals. We report the second case of Pneumocystis jirovecii pneumonia and COVID-19 co-infection in a renal transplant recipient in Poland.

8.
Hemato ; 3(1):111, 2022.
Article in English | ProQuest Central | ID: covidwho-1818069

ABSTRACT

Background. Hypercoagulable state and endothelial cell activation are common alterations in patients with COVID-19. Nevertheless, the hypothesis of persistent hypercoagulability and endothelial cell activation following recovery from COVID-19 remains an unresolved issue. Objectives. To investigate the persistence of endothelial cell activation and hypercoagulability after recovery from COVID-19. Patients/Methods. COVID-19 survivors (n = 208) and 30 healthy individuals were enrolled in this study. The following biomarkers were measured: procoagulant phospholipid-dependent clotting time (PPL-ct), D-Dimer, fibrin monomers (FM), free Tissue factor pathway inhibitor (free-TFP)I, heparinase, and soluble thrombomodulin (sTM). Antibodies against SARS-CoV-2 (IgG and IgA) were also measured. Results. The median interval between symptom onset and screening for SARS-CoV-2 antibodies was 62 days (IQR = 22 days). Survivors showed significantly higher levels of D-Dimers, FM, TFPI, and heparanase as compared to that of the control group. Survivors had significantly shorter PPL-ct. Elevated D-dimer was associated with older age. Elevated FM was associated with female gender. Elevated heparanase was independently associated with male gender. Decreased Procoag-PPL clotting time was associated with female gender. One out of four of COVID-19 survivors showed increase at least one biomarker of endothelial cell activation or hypercoagulability. Conclusions. Two months after onset of COVID-19, a significant activation of endothelial cells and in vivo thrombin generation persists in at least one out of four survivors of COVID-19. The clinical relevance of these biomarkers in the diagnosis and follow-up of patients with long COVID-19 merits to be evaluated in a prospective clinical study.

9.
Journal of the International Association of Providers of AIDS Care ; 21:16, 2022.
Article in English | EMBASE | ID: covidwho-1817142

ABSTRACT

Background: In sub-Saharan Africa, people living with HIV (PLHIV) face challenges accessing quality health care services, including barriers to care associated with widespread stigma and discrimination in health settings. Here, we present the results and lessons from a training program on stigma elimination rolled out in the city of Yaoundé, Cameroon within the framework of the joint IAPAC-UNAIDS Fast-Track Cities initiative. Method: Trainings were conducted as hybrid on-line and in-person for health workers and paraprofessional navigators employing self-narrated audio-visual training modules approved by the Cameroon National Aids Control Committee (NACC). Pre- and post-training questionnaires were administered to assess knowledge change across two modules: Human Rights and Integrating Stigma Elimination into Daily Practice. Results: A total of 417 health workers across 70 health facilities enrolled for the onsite training, while 671 across 37 health facilities registered for online training. For the onsite training sessions, average pre- and post-test scores for the module covering basics on human rights were 56% and 73%, respectively. Baseline score average for self-administered online trainings on human rights was 83% and 85% for post-training assessments. For the module covering integration of stigma elimination into daily practice, health worker overall knowledge gain in the pre- and post-test assessments was 49% to 69% for onsite trainees, and 85% to 87% for health workers enrolled online. Conclusion: Despite the COVID-19 pandemic, a blend of onsite and online training contributed to knowledge gains, especially among onsite trainees. Gauging the degree of knowledge improvement among self-administered online trainees was limited as health workers could repeat trainings over an extended period when compared to their onsite counterparts. Although the training of health workers is an entry point for stigma elimination, ongoing capacitation and follow up with the facility managers is critical for the attainment of stigma free health facilities.

10.
Journal of the International Association of Providers of AIDS Care ; 21:15, 2022.
Article in English | EMBASE | ID: covidwho-1817140

ABSTRACT

Background: The goal of HIV treatment is sustained viral load suppression. Early initiation of ART and access to clientcentered, differentiated, high-quality, stigma-free care is a prerequisite of long-term retention and viral load suppression. Method: 2,374 PLHIV from 5 cities (Lagos, Kinshasa, Yaoundé, Lusaka, and Kigali) were surveyed about their perceptions of the quality of care they receive across the eight domains of HIV understanding, linkage to HIV care, engagement in HIV care, ART adherence, HIV counseling, secondary HIV prevention, whole person care, and interpersonal communication. Implementation took place between January-April 2020. Results: Among 2,374 respondents, there was a similar gender distribution across both regions with women comprising 47-70%. InWCA, 37-50% reported initiated ART on the same day as HIV diagnosis, with 63-73% reporting initiation within the WHO-recommended seven days. Lagos, Kinshasa, and Yaoundé reported same-day and within seven days of ART initiation ranging from 51% and 68%. In terms of differentiated service delivery, in WCA, 37%- 50% reported having initiated ART on the same day, with 63-73% reporting it same day or within less than seven days. In Lusaka and Kigali, respondents reported same-day ART initiation at 34-56%, with 47-65% having received ART on same day or in less than seven days from HIV diagnosis. 37%-53% of respondents reported they were either not virally suppressed or they did not know if that had an undetectable viral load. Conclusion: A third to a half of respondents reported not initiating ART within the WHO-recommended seven days of HIV diagnosis. In two cities, respondents reported continuation of 1-2 monthly clinic visits despite the WHO recommendation of 3-6 monthly visits. A third to a half reported not being undetectable or not knowing their viral load status. A follow-up survey looking closely at the impact of COVID-19 on HIV services and perceived QoC is recommended to clearly assess impact on WHO recommendations for ART initiation.

11.
Journal of the International Association of Providers of AIDS Care ; 21:10-11, 2022.
Article in English | EMBASE | ID: covidwho-1817139

ABSTRACT

Background: Men have been left behind in the HIV response in sub-SaharanAfrica. Health4Men is a comprehensive HIV prevention and treatment programme, integrated into City of Johannesburg public-sector primary health facilities. Services include demand creation, outreach, PrEP, PEP, condom, and lubricant provision, HIV testing and treatment services, and sexual and reproductive health services. PrEP has the potential to impact on incident infections but has not been implemented at scale in South Africa. Method: We used routine data at five Health4Men sites in Johannesburg to examine trends in number of men testing HIV negative, offered PrEP, started on PrEP and number of men receiving PrEP per quarter, from October 2019 to March 2021. October 2019 toMarch 2020 is considered pre-COVID, April to June 2020 the lockdown period, July to December 2020 post-COVID, and January to March 2021 a recovery period. Results: At all sites, for the complete 18-month period, 34% of men who tested HIV negative were assessed to be high risk and offered PrEP (5832 men). 26% of those men accepted and initiated PrEP (1545 men). Although the offer rate decreased from 43% of HIV negative men pre-COVID (1365 men offered PrEP per quarter) to 31% post-COVID (860 men offered PrEP per quarter), uptake increased from 20% of men offered PrEP to 33%. The number of men remaining on PrEP decreased from 1234 pre-COVID, to 967 during lockdown, and 1070 for the post-COVID period (13% decrease). This recovered to 1305 in March 2021. Conclusion: These findings have implications for scaling up and integrating PrEP services during COVID-19 and beyond. Percentage uptake increased with decreased number of men offered PrEP, likely due to greater time spent counselling each client. Retention on PrEP was affected more than new initiations, and innovative methods of supporting adherence during COVID-19 waves are needed, e.g., enhanced virtual communication.

12.
Journal of the International Association of Providers of AIDS Care ; 21:3, 2022.
Article in English | EMBASE | ID: covidwho-1817138

ABSTRACT

Introduction: After the first diagnosis of COVID-19 on March 9, 2020, New Orleans, Louisiana had an early, rapid increase in cases, distinguished as the fastest-growing COVID outbreak worldwide. The University Medical Center-New Orleans (UMCNO), a safety net hospital in New Orleans, provided 24-hour access to routine HIV screening throughout the pandemic when many organizations halted screening services. Description: UMCNO implemented the Frontlines of Communities in the U.S. (FOCUS) grant funded HIV testing program in 2013, which integrated automated electronic medical record (EMR) driven routine HIV testing into normal hospital workflow, with system-wide policy changes to support sustainability. Two full-time navigator positions facilitate linkage to care for patients living with HIV identified through testing. Lessons Learned: Over 100,000 HIV tests were conducted at UMCNO between 2013 and 2020, with a HIV-seropositivity rate of approximately 0.9%. With implementation of stay-at-home orders, monthly average Emergency Department (ED) visits from April to June 2020 decreased to 65% of the November 2019 - January 2020 pre-pandemic levels, with monthly averages for HIV tests decreasing to 57% compared to the same pre-COVID quarter. Average monthly ED visits later increased, but remained lower than pre-pandemic levels (e.g., 7539 in the November 2019-January 2020 pre-COVID quarter compared to 6264 in the July - September 2020 quarter). Linkage to care rates remained consistently high (Table 1), proportional to identified positive diagnoses throughout 2020. Recommendations: UMCNO's FOCUS program integrated HIV screening into hospital workflow. As such, our hospitalmaintained testing, albeit at a reduced rate, during the months the stay-at-home orders were in place in New Orleans. The program maintained routine HIV testing and linkage services through EMR automation (best practice advisories) to ensure all eligible patients are offered testing when appropriate.

13.
Journal of the International Association of Providers of AIDS Care ; 21:4, 2022.
Article in English | EMBASE | ID: covidwho-1817137

ABSTRACT

Background: The HIV epidemic is a major public health problem in Mozambique. HIV patients retention in care and treatment is still among the most disturbing challenges. The National Health Service has adopted the differentiated models of service delivery for antiretroviral therapy to adapt the response to the needs of users. Thus, the Ministry of Health in collaboration with its partners established a partnership with public pharmacies outside the health facilities (FARMAC) to dispense antiretroviral drugs to patients in treatment. Method: Four FARMAC pharmacies in Maputo City were included in the strategy between September 2019 and August 2020. Eleven pharmacists from FARMAC were trained to dispense antiretroviral drugs and in counselling to enforce adherence to antiretroviral treatment. Education sessions and pamphlets were used to disseminate the strategy at health facilities. Patients older than 10, in the first line drugs, with good adherence, undetectable viral load, and without the need to take prophylaxis therapy were invited to participate. Those who consented were referred to the pharmacy of their choice. Patients received monitoring calls to collect their medication and attend clinical consultations timely. Results: About 2745 patients used FARMAC pharmacies through the intervention. Of those, 99% remained in HIV care and treatment. Adherence to the strategy was higher when associated to three months drugs collection. Only 26 patients interrupted their participation mainly (18 patients) due to repeated absences. Conclusion: Public pharmacies outside the health facilities are potentially an additional model to differentiated models for HIV service delivery. The strategy reduced the number of visits to the health facilities, demonstrating an appealing option in COVID-19 restrictions context and alike. Moreover, it illustrates patients centered models efficacy in retention improvement.

14.
Journal of the International Association of Providers of AIDS Care ; 21:6-7, 2022.
Article in English | EMBASE | ID: covidwho-1817135

ABSTRACT

Background: SARS-CoV-2 pandemic had a negative impact not only on diagnostic and therapeutic services but also on prevention, including HIV screening. In this study we evaluated and compared the impact of the pandemic on HIV testing in healthcare and community settings in Milan. Method: We considered the HIV screening tests performed between 01/01/2019 and 10/06/2021 in two local hospitalbased STIs outpatient clinics and in a community-based HIV testing facility. We then compared the two settings in pre COVID (before Mar2020) and post COVID (Mar2020-Jun2021) period in terms of number of tests performed, test results and age, sex and nationality of the subjects tested. Results: 4106 HIV screening tests have been performed (30.8% healthcare setting, 69.2% community setting). Globally, the community setting tested younger subjects, more females, and fewer foreigners, with a lower HIV prevalence (Tab1). In the healthcare setting, in the post COVID period there has been a decrease in the number of tests performed (Tab4), with older subjects and fewer females tested (Tab2). HIV prevalence remained quite high (Tab3). In the community setting, in the post COVID period there has been also a decrease in the number of tests performed, mostly due to lockdown (Mar - Jun 2020, Fig1). Indeed, after restricting to the period of Jul 2020 - Jun 2021, the average number of HIV-test/month was similar to pre COVID era. Younger subjects, fewer females and a lower HIV prevalence have been found in post COVID period. Conclusion: Both settings have reduced their activity due to the pandemic. The prevalence of HIV was high in the healthcare setting, possibly because of subjects attending the service while symptomatic or at higher risk. The differences between the subjects tested in the two settings demonstrate the importance of an integrated approach to ensure greater coverage of HIV screening campaigns.

15.
Journal of the International Association of Providers of AIDS Care ; 21:11, 2022.
Article in English | EMBASE | ID: covidwho-1817134

ABSTRACT

Introduction: State-wide lockdowns for COVID-19 pandemic caused major disruptions for People Living with HIV (PLHIV) registered for treatment with Public Antiretroviral Treatment (ART) Centres in Mumbai. They faced enormous difficulties in reaching their treatment centres while many PLHIVs, being migrants in the city, travelled back to their native districts. These situations posed serious challenges for HIV program implementation to ensure UNAIDS treatment goals of retention in care. It was also compounded due to 53% of PLHIV, being unreachable by phone among those who missed their appointments at ART Centres, with resultant treatment interruptions. Description: Mumbai Districts AIDS Control Society (MDACS) launched ARTMitr (Mitr meaning friend), the strategy to guide PLHIV for services based on their geo-location during the lockdown. PLHIV who missed appointments received a short SMS vernacular text message from ARTmitr with a helpline number. The patients who responded to SMS and successful SMS beneficiaries received personalized tele-guidance based on their current location and their ability to reach the nearest ART centre. The ARV refills through community refill sites were initiated through training of outreach staff. The mobile web form captured refill data from community sites for real- time updates at ART centre. Lessons Learned: During April-June 2021, SMS notifications were sent to 9524 PLHIV and were successfully received by 5958 (62%). Tele-guidance was provided to 3242 (54%) patients. ARV medicines in transit were facilitated from nearby treatment centers for 1982 patients and 475 were advised to reach local ART centre. The patient centric services of Community ARV refills and courier services were arranged for continuum of care. Innovative services of e-transfer and e-consultation were launched for PLHIVs using digital technology. Recommendations: ARTmitr facilitated to reach PLHIVs for accessible ARV services during COVID lockdown through the community ARV refills and e-consultation services.

16.
J Int Assoc Provid AIDS Care ; 21:23259582221075431, 2022.
Article in English | EMBASE | ID: covidwho-1817133

ABSTRACT

The proceedings contain 36 papers. The topics discussed include: Austin/Travis County fast-track cities: developing a local action plan through stakeholder engagement;impact of community pharmacies on access to point-of-care tests for HIV and hepatitis C and B infections: an observational, cross-sectional study;routine HIV screening in the era of COVID-19;modelling the interaction between depression and HIV incidence in Manicaland, East Zimbabwe;TB treatment initiation time in HIV positive patients: implications for TB treatment outcomes;the effect of using FARMAC pharmacies in strengthening the differentiated models of service delivery for antiretroviral therapy;and associations of income and demographics with care continuum outcomes: a zip code level analysis in 36 US cities.

17.
Clinical Cancer Research ; 27(6 SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1816891

ABSTRACT

Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. Results: Clinical agreement studies were performed in 77 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15% (95% CI: 19.22% ∼74.87%), 61.54% (95% CI: 31.58% ∼86.14%), and 97.53% (95% CI: 91.36% ∼99.70%) for samples collected on 0-7 days, 8-14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% ∼99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgG testing.

18.
Journal of Acquired Immune Deficiency Syndromes ; 89(5):511-518, 2022.
Article in English | ProQuest Central | ID: covidwho-1816363

ABSTRACT

Background:We aim to investigate the infection rate, the clinical characteristics and outcomes of COVID-19-disease in a cohort of people living with HIV in Madrid (Spain), during the first year of pandemics.Setting:Observational single-center study, in which we included all HIV-infected patients (aged ≥ 18 years) with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as of February 28, 2021, at the Hospital Universitario 12 de Octubre.Methods:Confirmed disease was defined as any patient with a positive antigen test, reverse transcriptase polymerase chain reaction, or serology for SARS-CoV-2. We compared the characteristics of patients with mild disease (asymptomatic included) with those with moderate or severe disease (requiring admission).Results:Of 2344 HIV-infected patients, 158 (82.9% male;median age, 46.5 years) were diagnosed with SARS-CoV-2 (infection rate, 6.74%;95% confidence interval, 5.79 to 7.83). Thirty-nine individuals (24.7%) had moderate or severe disease, 43.7% had mild disease, and 31.6% were asymptomatic. Hypertension (23.4%) and obesity (15.8%) were the most prevalent comorbidities;12.7% had at least 2 comorbidities. One hundred forty-five patients (97.3%) had RNA-HIV viral load of <50 copies per milliliter, and only 3 had CD4 cell count of <200 cells per cubic millimeter before infection. Of those admitted to hospital, 59% required oxygen support and 15.4%, invasive mechanical ventilation. Five patients died. None of the patient taking tenofovir-disoproxil-fumarate required admission. In the multivariate analysis, age remained as the only independent factor for moderate-severe disease (odds ratio, 1.09;95% confidence interval 1.04 to 1.14;P < 0.001).Conclusions:People living with HIV are at risk of severe SARS-CoV-2 infection. Age was the only variable with an independent association with moderate-severe disease, after adjusting by comorbidities and other factors.

19.
The Lancet ; 399(10336):1686-1687, 2022.
Article in English | ProQuest Central | ID: covidwho-1815320

ABSTRACT

Only one staff member in full personal protective equipment sat at the front, screening patients individually and escorting them into examination rooms. An intern at the hospital made sure that he was linked to our clinic. Because of his compromised immune system, he told me that simply coming to the clinic felt like a huge risk. Black patients in the USA have worse outcomes at each step along the HIV care continuum due to the same daunting structural and social factors Ray faced—the housing instability, the poverty and unemployment, the food insecurity, the structural racism. In his case, acknowledging the trauma and excavating the pain were part of his journey to achieving and maintaining an undetectable viral load and establishing a foundation for human flourishing.

20.
Computers in Biology and Medicine ; 145, 2022.
Article in English | EMBASE | ID: covidwho-1814279

ABSTRACT

Starting three decades ago and spreading rapidly around the world, acquired immunodeficiency syndrome (AIDS) is an infectious disease distinct from other contagious diseases by its unique ways of transmission. Over the past few decades, research into new drug compounds has been accompanied by extensive advances, and the design and manufacture of drugs that inhibit virus enzymes is one way to combat the AIDS virus. Since blocking enzyme activity can kill a pathogen or correct a metabolic imbalance, the design and use of enzyme inhibitors is a new approach against viruses. We carried out an in-depth analysis of the efficacy of atazanavir and its newly designed analogs as human immunodeficiency virus (HIV) protease inhibitors using molecular docking. The best-designed analogs were then compared with atazanavir by the molecular dynamics simulation. The most promising results were ultimately found based on the docking analysis for HIV protease. Several exhibited an estimated free binding energy lower than −9.45 kcal/mol, indicating better prediction results than the atazanavir. ATV7 inhibitor with antiviral action may be more beneficial for infected patients with HIV. Molecular dynamics analysis and binding energy also showed that the ATV7 drug had more inhibitory ability than the atazanavir drug.

SELECTION OF CITATIONS
SEARCH DETAIL